Eliem Therapeutics ($ELYM) experienced significant stock price fluctuations following news related to Amgen ($AMGN). On September 24, $ELYM saw a 55% increase, but by September 25, it had dropped by 52% from its all-time high and declined by 16% that day. The stock continued to be volatile, trading at $5 on September 26 after a private offering at $3.84. Other biotech stocks also showed mixed performance, with Cullinan Oncology ($CGEM) declining by 25% and 6.5% that day, Argenx ($ARGX) gaining 5%, and Astria Therapeutics ($ATXS) dropping by 20%.